Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. by Wawrzynczak, E. J. et al.
Br. .1. Cancer (1990), 62, 410-414 t. Macmillan Press Ltd., 1990
Selective cytotoxic effects of a ricin A chain immunotoxin made with the
monoclonal antibody SWAll recognising a human small cell lung cancer
antigen
E.J. Wawrzynczak', E.J. Derbyshire', R.V. Henry', G.D. Parnell', A. Smith2, R. Waibel2
& R.A. Stahel2
'Drug Targeting Laboratory, Section ofMedicine, Institute ofCancer Research, Sutton, Surrey SM2 5NG, UK; and 'Division of
Oncology, Department ofMedicine, University Hospital, CH-8091 Zurich, Switzerland.
Summary The potential of mouse monoclonal antibodies for recognising different antigens associated with
human small cell lung cancer (SCLC) to form active immunotoxins was assessed by an indirect in vitro
screening assay. The screening agent used was a conjugate made by linking ricin A chain to a sheep
anti-mouse IgG Fab' fragment via a disulphide bond. The monoclonal antibodies SWA 11 and SWA20 both
mediated the toxic effects of ricin A chain against the HC12 classic SCLC cell line in dose-dependent fashion.
The SWA antibody was the more effective; in combination with the screening agent at a concentration of
I X 10-7 M, it inhibited the incorporation of [3H] leucine into HC12 cells by 94% compared with only 44%
inhibition in the case of SWA20. An immunotoxin made by the direct chemical conjugation of ricin A chain to
SWA II exhibited selective toxic effects upon HC12 cells in tissue culture inhibiting the incorporation of [3H]
leucine by 50% at a concentration (IC50) of 6.2 x 10- OM and by 98% at I x 10-7M. SWAl l-ricin A chain had
an IC50 of 4.4 x 10- OM against the NCI-H69 classic SCLC cell line but showed no cytotoxic activity against
the human lung adenocarcinoma cell line NCI-H23 at a concentration of 1 x 10-8M.
Lung cancer is now the most common malignancy in men
world-wide and is expected to overtake breast cancer as the
leading cause of mortality in women. Small cell lung cancer
(SCLC), which accounts for about 25% of new cases, differs
from other lung neoplasms in two important respects. Firstly,
SCLC is highly metastatic. Most patients present with
mediastinal metastases, extrathoracic metastases, or both.
Secondly, SCLC is highly chemoresponsive. Combination
chemotherapy results in high remission rates but most
patients die of their disease within two years following the
development of drug resistance and few patients achieve
long-term survival. There is a clear need, therefore, to inves-
tigate cytotoxic agents which act by a different mechanism
from the agents in current use and which can be administered
systemically. A novel approach is the use of monoclonal
antibodies to deliver toxic proteins, such as the ribosome-
inactivating protein ricin A chain, to sites of tumour.
Antibody-toxin conjugates, or immunotoxins (ITs), made
with monoclonal antibodies recognising tumour-associated
antigens have demonstrated selective toxic effects against
human tumour cells in tissue culture and in animal models of
cancer, and are currently undergoing clinical trials in patients
(Blakey et al., 1988).
The First International Workshop on SCLC Antigens
identified several different groups, or clusters, of monoclonal
antibodies that recognise discrete cell-surface antigens
associated with SCLC. Each cluster of antibodies displayed a
characteristic spectrum of binding to normal and malignant
tissues and cell lines of pulmonary, neuroendocrine and
epithelial origin (Souhami et al., 1988). A number of mono-
clonal antibodies making up clusters designated w4 and 5A
have been described previously (Stahel et al., 1988). SWA1 1,
which is associated with cluster w4, shows strong reactivity
with both classic and variant SCLC cell lines in vitro. This
antibody localises efficiently in human SCLC tumour xeno-
grafts in vivo (Smith et al., 1989) and inhibits tumour growth
when conjugated to '3'I (Smith et al., 1990). SWA20, belong-
ing to cluster SA, recognises a sialoglycoprotein antigen ex-
pressed selectively by a proportion of SCLC cell lines and
primary SCLC tumours (Waibel et al., 1988; Maier et al.,
1989).
In this study, we have assessed the potential of the anti-
SCLC antibodies to form cytotoxic agents with ricin A chain
by using a modified version of the indirect in vitro screening
procedure developed by Weltman et al. (1987) and Till et al.
(1988). When the human classic SCLC cell line HC12 was
exposed to the SWA 11 antibody and then incubated with the
screening agent, sheep anti-mouse IgG Fab' fragment linked
to ricin A chain (SAMIgG Fab'-ricin A chain), cellular pro-
tein synthesis was inhibited in dose-dependent fashion. An IT
made by the direct chemical conjugation of ricin A chain to
the SWAl1 antibody displayed selective toxic effects upon
the HC12 cell line, confirming the prediction of the indirect
assay.
Materials and methods
Materials
Castor bean cake derived from the seeds of Ricinus communis
of Sri Lankan origin was a gift of Croda Premier Oils, Hull,
Humberside, England. The anti-SCLC mouse monoclonal
antibodies, SWAl 1 and SWA20, were purified from hyb-
ridoma supernatants as described by Smith et al. (1989). The
control mouse monoclonal antibody raised against vesicular
stomatitis virus, 2AL-1, was purified from ascitic fluid (For-
rester et al., 1984). All three antibodies are of the IgG2a
subclass. The human classic SCLC cell line HC12 (Duchesne
et al., 1987) was the gift of Dr. G. Duchesne, Institute of
Cancer Research, Sutton. The human classic SCLC cell line
NCI-H69 and the human lung adenocarcinoma cell line NCI-
H23 (Carney et al., 1985) were kindly provided by Dr. V.
Macaulay, Institute of Cancer Research, Sutton.
Tissue culture medium RPMI-1640 and fetal calf serum
(FCS) were purchased from Gibco Ltd., Paisley, Scotland.
The 96-well and 24-well sterile tissue culture plates (Nunclon)
and flat-bottomed 96-well mircoelisa plates (Immulon 2) were
obtained from Dynatech Laboratories Ltd., Billingshurst,
Sussex, England.
Sephadex G25(SF), Sephacryl S200(HR), Blue Sepharose
CL-6B and N-succimrimidyl 3-(2-pyridyldithio) propionate
(SPDP) were purchased from Pharmacia Ltd., Milton
Keynes, Bucks, England. Streptavidin-biotinylated
horseradish peroxidase (HRP) complex (RPN. 1051) and L-
[4, 5-'H] leucine (TRK. 170) were from Amersham Interna-
tional plc, Amersham, Bucks, England. (Sheep) Anti-mouse
Correspondence: E.J. Wawrzynczak.
Received 24 January 1990; and in revised form 20 April 1990.
17" Macmillan Press Ltd., 1990 Br. J. Cancer (I990), 62, 410 414IMMUNOTOXIN AGAINST SMALL CELL LUNG CANCER 411
IgG F(ab')2 fragment (M-1522), dithiothreitol (DTT), o-
phenylenediamine and thimerosal were from Sigma Chemical
Co. Ltd., Poole, Dorset, England. N-iodoacetyl-N-
biotinylhexylenediamine (iodoacetyl-LC-biotin) was from
Pierce & Warriner (UK) Ltd., Chester, Cheshire, England.
5,5'-dithiobis (2-nitrobenzoic acid) (Ellman's reagent) was
purchased from Aldrich Chemical Co. Ltd., Gillingham,
Dorset, England. Casein (hammersten grade) was obtained
from BDH Ltd., Poole, Dorset, England. All other reagents
were of the highest available purity.
Preparation of immunotoxins:
Purification of ricin A chain Ricin was isolated from an
aqueous extract of defatted castor bean cake using the
methods described by Cumber et al. (1985). Ricin A chain
was isolated from the toxin by reductive cleavage and further
purified using immobilised asialofetuin as described by For-
rester et al. (1984).
Preparation of immunotoxins with mouse monoclonal
antibodies Ricin A chain was attached to the SWAl1 and
SWA20 monoclonal antibodies via a disulphide bond using
procedures described in detail by Cumber et al. (1985).
Briefly, 2-pyridyl disulphide groups were introduced into
SWA 1 and SWA20 at an average modification level of
about 1.5 groups per antibody by reaction with the SPDP
reagent. The antibodies so derived were reacted overnight
with an excess of freshly reduced ricin A chain. In each case,
the reaction mixture was then applied to a column of
Sephacryl S200 (HR) and the material which eluted at a
position corresponding to a relative molecular mass (Mr) of
approximately 180,000-210,000 was pooled. Analysis by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) indicated that the predominant IT species in
these preparations contained one molecule of ricin A chain
linked to one molecule of antibody. The preparations also
contained smaller amounts of more highly substituted con-
jugate molecules and uncoupled antibody. The preparation of
2AL-1-ricin A chain by a similar procedure has been des-
cribed previously (Forrester et al., 1984).
Preparation of SAMIgG Fab'-ricin A chain SAMIgG Fab'-
ricin A chain was synthesised by a method based on the
work of Masuho & Hara (1980) and Till et al. (1988). The
F (ab')2 fragment of SAMIgG was dissolved to give a final
concentration of about 1 mg ml-' in 20 mM Tris-HCI buffer
containing 0.14M NaCl, 2 mM EDTA, pH 8.2 (TE buffer).
2-Mercaptoethanol (as a 20 mM solution in TE buffer) was
added to a final concentration of 2 mM and the mixture was
incubated for I h at 37°C. Ellman's reagent (as a 50 mM
solution in TE buffer) was then added to a final concentra-
tion of 5 mM and the mixture incubated for 1 h at room
temperature. The mixture was then dialysed three times
against 41 of 20 mM sodium phosphate buffer containing
0.14M NaCl, I mM EDTA, pH 6.5 at 4°C . To 7 ml of the
solution containing about 5 mg of Fab' substituted with Ell-
man's reagent was added 7 ml of a solution containing
7.5 mg ricin A chain in 20 mM sodium phosphate buffer
containing 0.14M NaCI, I mM EDTA, pH 7.5 (PE buffer).
The reaction mixture was left overnight at room temperature,
then concentrated to about 8 ml by ultrafiltration using an
Amicon PM10 membrane and subjected to gel permeation
chromatography on a column (90 cm x 1.6 cm diameter) of
Sephacryl S200 (HR) equilibrated with PE buffer. The pooled
fraction corresponding to Fab'-ricin A chain (Mr, approx-
imately 80,000) was concentrated to about 4 ml by
ultrafiltration, dialysed into 50 mM sodium phosphate buffer,
pH 7.5, and applied to a column (17 cm x 1.2 cm diameter)
of Blue Sepharose CL-6B equilibrated with the same buffer.
The Fab'-ricin A chain eluted from the column with 50 mM
sodium phosphate buffer containing 0.5 M NaCl, pH 7.5, and
was judged by SDS-PAGE to be essentially free from con-
tamination by free ricin A chain and unconjugated antibody
fragments. The product was sterilised by filtration and stored
at 4°C.
Measurement ofSAMIgG Fab' binding to mouse monoclonal
antibodies
Synthesis of SAMIgG Fab'-LC-biotin SAMIgG F (ab')2 at
about 1 mg ml-' in TE buffer was treated with DTT at a
final concentration of 1OmM for 2 h at room temperature.
The reduced Fab' fragment was purified free from excess
reducing agent by gel filtration on a column of Sephadex
G25 (SF) equilibrated with N2-flushed TE buffer. A 20-fold
molar excess of N-iodoacetyl-LC-biotin, prepared as a solu-
tion in dimethylformamide at 7.6mgml-', was added and
the reaction allowed to proceed for 1 h at room temperature.
SAMIgG Fab'-LC-biotin was then isolated by gel filtration
on a column of Sephacryl S200 (HR) equilibrated with PE
buffer.
Enzyme-linked immunosorbent assay Mouse monoclonal
antibody was adsorbed to microelisa plates by incubating
each well with 100 tLI of antibody solution, prepared at
different concentrations in 15 mM sodium carbonate/35 mM
sodium bicarbonate buffer, pH 9.6, overnight at 4°C in a
humidified atmosphere. The subsequent steps were carried
out at room temperature. The plates were washed four times
with casein buffer (10 mM Tris-HCI, pH 7.6 containing
0.15 M NaCl, 0.5% (w/v) casein and 0.02% (w/v) thimerosal)
using a Dynatech 'Miniwash' plate washer. Wells were
incubated in casein buffer for 30 min and the buffer was then
removed. SAMIgG Fab'-LC-biotin in casein buffer at a con-
centration of 1 igml1' was then added to the wells of the
plate in 100jil volumes. The plates were incubated for 2 h.
After washing four times with casein buffer as above, 100 jil
of streptavidin-biotinylated HRP complex diluted 1:1000 in
casein buffer was added to each well for 1 h. The plates were
washed three times with casein buffer and once with
phosphate-buffered saline (PBS). The wells were then
incubated with 100plA of o-phenylenediamine solution (40 mg
in 100 ml 52 mM Na2HPO4/24 mM citric acid containing 20jil
100 vols. H202) for 10 min. The development of colour was
stopped by the addition of 50pA 12.5% (v/v) H2SO4. The
plates were read at 492 nm on an automated plate reader.
Cytotoxicity experiments in tissue culture
The human SCLC cell lines HC12 and NCI-H69, growing in
the form of multicellular spheroids in suspension, were
routinely maintained in RPMI-1640 supplemented with 1%
(v/v) 0.24 M glutamine solution and 10% (v/v) FCS (heat-
inactivated) in a humidified atmosphere of 5% (v/v) CO2 in
air at 37°C. For cytotoxicity assays, the spheroids were first
suspended in PBS and then disaggregated mechanically by
repeated passage through a 0.6 mm gauge syringe needle to
produce a suspension consisting predominantly of single
cells.
In indirect assays of IT cytotoxicity, samples of mouse
monoclonal antibody in PBS were distributed in 0.1 ml
volumes into the wells of a 96-well tissue culture plate. The
HC12 singled cell suspension, 0.1 ml containing 1 x 105 cells,
was added to each well and incubated for 1 h at 4°C. The
cells were then washed once with cold PBS and resuspended
in 0.2 ml of leucine-free RPMI-1640/10% FCS/2.4 mM
glutamine (assay medium) alone, or in assay medium con-
taining SAMIgG FAb'-ricin A chain. Following incubation
for 47 h at 37°C, 1 iLCi of [3H] leucine was added to each well
and the cultures were incubated for a further 24 h at 37°C
before the cells were harvested on filters using a Titertek
automated cell harvester. The incorporation of [3H] leucine
was determined by liquid scintillation counting of the filters
in an LKB Rackbeta Liquid Scintillation Counter. In con-
tinuous assays of cytotoxic activity using the HC12 and
NCI-H69 cell lines, 0.1 ml samples of antibody, IT or ricin
prepared at different concentrations in assay medium, were
mixed with 0.1 ml of a singled cell suspension and the cells
were incubated without washing for 48 h at 37°C before
pulsing with [3H] leucine for 24 h, harvesting and counting of
radioactivity as described above. All assays were performed
in quadruplicate.412 E.J. WAWRZYNCZAK et al.
The human lung adenocarcinoma cell line NCI-H23 was
routinely maintained in RPMI-1640/10% FCS/2.4 mM
glutamine in a humidified atmosphere of 5% (v/v) CO2 in air
at 37°C. Cells were harvested with trypsin/versene, washed
with fresh medium, and distributed in1 ml volumes into the
wells of a 24-well sterile tissue culture plate to give a total of
1 x105 cells per well. The plates were incubated for 48 h at
37°C to allow the cells to adhere to the plate. The medium
was removed by aspiration and replaced with 0.9 ml assay
medium. Samples (0.1 ml) of IT or ricin at different concen-
trations in assay medium were then added to cell cultures in
triplicate and the plates incubated for 24 h. [3H] Leucine at
1 JACi per well was added and the incubation continued for a
further 24 h. The cells were washed three times with PBS,
fixed once with 5% (w/v) trichloroacetic acid, washed with
methanol and dried. The content of each well was solubilised
by incubation with 0.2 ml of1 M NaOH for1 h at 37°C. The
incorporation of [3H] leucine was determined by liquid scin-
tillation counting of 0.15 ml samples of the solubilised cel-
lular contents.
Results
Indirect assay ofimmunotoxin cytotoxicity
The ability of the two anti-SCLC monoclonal antibodies,
SWA1I and SWA20, to mediate ricin A chain toxicity
against the human classic SCLC cell line HC12 was tested by
an indirect screening assay in vitro. Both monoclonal
antibodies bound to a high proportion of HC12 cells by
indirect immunofluorescence analysis, SWA1I giving the
greater intensity of fluorescence staining on cells treated with
the antibodies at identical concentration. A third monoclonal
antibody, 2AL-1, found not to bind to HC12 cells by indirect
immunofluorescence analysis, was included as a negative con-
trol. The binding of the SAMIgG Fab' fragment to the three
mouse monoclonal antibodies was measured by an enzyme-
linked immunosorbent assay using the biotinylated Fab' frag-
ment. SAMIgG Fab'-LC-biotin bound to immobilised mouse
antibody was detected using a streptavidin-biotinylated HRP
complex. As shown in Figure 1, there was no significant
difference between the binding curves for the three monoc-
lonal antibodies, indicating that the Fab' fragment bound
similarly to each antibody.
In the indirect assay of IT cytotoxicity, HC12 cells were
first treated with a single concentration of each of the three
monoclonal antibodies. The cells were then washed and
incubated with the screening agent, SAMIgG Fab'-ricin A
chain, at various concentrations. Figure 2 shows the effects
of these treatments on cellular protein synthesis. The incor-
poration of [3H] leucine was greatly reduced in cells treated
with SWA1 followed by the screening agent, compared with
cells in control cultures incubated with the screening agent
alone. This cytotoxic effect was dose-dependent; protein syn-
thesis was inhibited by 75% at a SAMIgG Fab'-ricin A chain
concentration of I x 10-iM and by 94% at the 10-fold
higher concentration of the screening agent. The inhibition of
protein synthesis was dependent upon the presence of the
screening agent because cells exposed to the SWA1 1 antibody
alone were not affected. Protein synthesis in HC12 cells
treated with SWA20 in combination with the screening agent
was also inhibited in a dose-dependent manner. However, the
effect was much weaker than that observed with SWAl1;
there was no significant inhibition of [3H] leucine incorpora-
tion at a SAMIgG Fab'-ricin A chain concentration of
I x Io-8 M and protein synthesis was inhibited by only 44%
with the screening agent at a concentration of 1 x l0-7M.
No significant effects were observed when the non-binding
antibody, 2AL-1, was tested in the assay in combination with
the screening agent. The results of the indirect assay
indicated that, although the screening agent bound equally
well to all three monoclonal antibodies, only the antibodies
able to bind to the HC12 cell line demonstrated cytotoxic
effects. The SWA 11 antibody was the most effective at
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Figure 1 Binding ofSAMIgG Fab'.fragment to mouse monoclonal
antibodies. Microelisa plates treated with SWAlI (a), SWA20
(0), or 2AL-1 (-) at various concentrations between 0.01 and
0.1ILg ml-, were exposed to a single concentration (1 jigml-) of
SAMIgG Fab'-LC-biotin and then to streptavidin-biotinylated
HRP complex. The absorbance at 492 nm developed by the
substrate solution was taken as a measure of the amount of the
Fab' fragment bound. Each point shown represents the arith-
metic mean value of sextuplicate determinations. The error bars
denote the standard deviations from the mean values unless
smaller than the symbols used.
120
0)
c
.0
C.)
C
0 ,- c
o0
C)
c
100
80
60
40
20-
0
10-8 10
7
Concentration of SAMIgG Fab'-ricin A chain (M)
Figure 2 Indirect assay ofimmunotoxin cytotoxicity. HC12 cells
exposed to SWAI 1 (0), SWA20 (0), or 2AL- (U) at a final
concentration of 25 tg ml-' for I h, were washed, incubated in
the presence of SAMIgG Fab'-ricin A chain at I x 10-iM,
2.5 x 10-8 M and I x lo-'M for 48 h and then incubated in the
presence of [3H] leucine for a further 24 h. The effects of these
treatments are expressed as the percentage of the [3H] leucine
incorporated by untreated control cell cultures
(>I00,000 c.p.m.). Each point shown represents the arithmetic
mean value of quadruplicate determinations of[3H] leucine incor-
poration. The error bars denote the standard deviations from the
mean values unless smaller than the symbols used. The [3H]
leucine incorporation ofcontrol cultures incubated with SAMIgG
Fab'-ricin A chain alone at I x l0- M was inhibited by less than
20%.
mediating the entry into the cells of ricin A chain delivered
by the SAMIgG Fab' fragment. This finding strongly sug-
gested that an IT made by linking ricin A chain directly to
the SWAI1 antibody would exert comparable cytotoxic
effects upon HC12 cells and other cells expressing the antigen
recognised by SWAl1.
Cytotoxic activity of ricin A chain immunotoxins made with
SWAII, SWA20and 2AL-1
The toxic effect of treating HC12 cells with an IT made by
linking ricin A chain directly to the SWAI1 antibody was
compared with the effect given by combination of the uncon-
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jugated SWA 11 antibody and the screening agent in the
indirect assay. Cells were treated in one of two ways. In one
arm of the assay, cells exposed to SWAl alone at various
concentrations for 1 h were washed and then incubated in the
presence of a single concentration of SAMIgG Fab'-ricin A
chain for 47 h. In the other arm of the assay, cells exposed to
SWA -ricin A chain at various concentrations for I h were
washed and then incubated in the presence of assay medium
alone for 47 h. Both treatments gave similar dose-dependent
cytotoxicity (Figure 3). The incorporation of [3H] leucine was
inhibited by 50% at a concentration (IC,)) of 7-8 x 10-9 M
showing that the indirect screening assay had indeed pro-
vided an accurate prediction of the cytotoxic potency of the
SWAll-ricin A chain IT against the HC12 cell line.
The potency of the SWAll-ricin A chain IT against the
HC12 cell line was further assessed by cytotoxicity
experiments in which the cells were cultured in the con-
tinuous presence of the IT (Figure 4 and Table I). SWAl 1-
ricin A chain inhibited protein synthesis with an IC50 of
about 6 x 101 M. This concentration was about 10-fold
lower than that observed when the cells were exposed to the
IT for only 1 h before incubation (Figure 3) indicating that
continuous exposure led to a higher uptake of the IT by the
cells. SWA20-ricin A chain demonstrated a substantially less
potent cytotoxic effect: its IC_, was about 2 x 10-8 M, that is,
more than 30-fold higher than the IC50 for SWAl 1-ricin A
chain (Figure 4) in accordance with the predictions of the
indirect assay of IT cytotoxicity. The SWA 11 and SWA20
ITs were both appreciably less toxic to the HC12 cell line
than ricin toxin itself which had an IC5) of about 5 x 10-'s M
(Figure 4). At the highest concentration tested, that is, at
I X 10-7 M, SWA1 l-ricin A chain inhibited protein synthesis
by 98% (Figure 4). At the same concentration, the isotype-
matched control IT, 2AL-1-ricin A chain, inhibited protein
synthesis by less than 15% (Figure 4) showing that the
cytotoxic effects observed in the presence of SWAll-ricin A
chain were not due to antigen-independent uptake of IT by
the cells. The observed cytotoxic effects of the SWAl IT
were dependent upon the covalent combination of the two
components of the conjugate. The SWA 11 antibody alone at
a concentration of I x 10-7 M, ricin A chain alone at a
concentration of I x 10-7 M, or a simple mixture of antibody
and A chain at the same concentrations had no effect on
protein synthesis by HC12 cells (not shown).
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Figure 3 Cytotoxic effects ofSWAJI-ricin A chain compared with
SWAl1-mediated cytotoxicity in the indirect assay. HC12 cells
were exposed either to SWA1 -ricin A chain at various concen-
trations between I x 10-`0M and I x 10-7M for 1 h followed by
incubation in assay medium for 47 h (0), or to SWAI I at the
same concentrations for I h followed by incubation in the
presence of SAMIgG Fab'-ricin A chain at 1 x 10' M for 47 h
(0). The cells were then incubated in the presence of [3H] leucine
for 24 h. The results are expressed as the percentage of the ['H]
leucine incorporated by control cell cultures (>80,000 c.p.m.).
The mean values and standard deviations of quadruplicate deter-
minations are shown. Error bars denote standard deviations from
the mean values unless smaller than the symbols used.
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Figure 4 Cytotoxic effects ofSWAII-ricin A chain, SWA20-ricin
A chain, 2AL-1-ricin A chain and ricin against the HC12 cell line.
HC12 cells were incubated for 48 h in the continuous presence of
SWAIl-ricin A chain (0), SWA20-ricin A chain (0), 2AL-1-
ricin A chain (U) or ricin (A) at the concentrations shown and
for a further 24 h in the presence of [3H] leucine. The represen-
tative results shown are expressed as the percentage of [3H]
leucine incorporated by untreated control cell cultures (>70,000
c.p.m.). The mean values and standard deviations of quadrup-
licate determinations are shown. Errors bars denote standard
deviations from the mean values unless smaller than the symbols
used.
Tablet CytotoxiceffectsofSWA 11-ricinAchain, 2AL-1-ricinAchain
and ricin against the HC12, NCI-H69 and NCI-H23 cell lines in tissue
culture
Cell line Agent IC50a (M)
SWA l-ricin A chain 6.3 ± 3.9 x 10- (3)
HC12 2AL-l-ricin A chain >5 x 10-8 (3)
Ricin 4.5 ± 1.4 x 10-'3 (3)
SWA lI -ricin A chain 4.4 ± 1.3 x 10-10 (3)
NCI-H69 2AL-l-ricin A chain >5 x 10-8 (2)
Ricin 1.2 ± 1.3 x 10-12 (3)
SWA II-ricin A chain > I x 10-8 (3)
NCI-H23 2AL-1-ricin A chain > I x 10-8 (2)
Ricin 1.2 ± 0.2 x 10-"1 (3)
'IC50 = concentration calculated to reduce[3H] leucine incorporation
by 50%. Thevaluesquotedarethemeanandstandarddeviationderived
from several experiments. The number ofexperiments in each case is
quoted in brackets after the values.
The ability of SWA1 1-ricin A chain to exert cytotoxic
effects against other human lung tumour cell lines was tested
using two cell lines, NCI-H69, a classic SCLC cell line ex-
pressing the antigen recognised by SWA 11, and, NCI-H23, a
lung adenocarcinoma cell line found not to bind SWAl1 by
indirect immunofluorescence analysis. SWAll-ricin A chain
inhibited the incorporation of [3H] leucine by NCI-H69 cells
upon continuous incubation in tissue culture with an IC50 of
about 4 x 10-10 M (Table I) comparable with its potency
against the HC12 cell line. Ricin was a more potent cytotoxic
agent than SWAl 1-ricin A chain against both SCLC cell
lines; the IC50 for ricin was 1,400-fold less than that of the IT
in the case of the HC12 cell line and about 370-fold less in
the case of the NCI-H69 cell line. 2AL-1-ricin A chain
exerted no significant cytotoxic effects against either cell line
at a concentration of 5 x 10-8 M. In contrast to the effects
observed against the two SCLC cell lines, SWAl1-ricin A
chain had no significant cytotoxic effects upon the non-SCLC
cell line NCI-H23 at a concentration of 1 x 10-8M.
Moreover, the SWA 11 IT at the same concentration was
unable to inhibit protein synthesis by a human non-lung
tumour cell line, the EJ bladder carcinoma cell line (not
shown).
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Discussion
In this study, we have shown that an indirect screening
procedure accurately predicted the cytotoxic potency of ITs
made by linking ricin A chain to the SWAl1 and SWA20
monoclonal antibodies against the human classic SCLC cell
line HC12 in tissue culture. The principle of indirect screen-
ing of antibody-mediated delivery of toxin to target cells was
introduced by Weltman et al. (1986, 1987) to enable the
analysis of hybridoma ascites and supernatants for the
presence of monoclonal antibodies that were likely to form
ITs with cytotoxic activity. The approach was validated by
Till et al. (1988) using a goat anti-mouse Ig Fab-ricin A
chain conjugate; there was good correlation between the
cytotoxic effects of a large panel of monoclonal antibodies
directed against lymphoid cells in the indirect assay and the
toxicity of the corresponding ITs made with these antibodies
to lymphoid cell lines. The assay we describe, using SAMIgG
Fab'-ricin A chain, will enable existing and novel monoclonal
antibodies recognising different antigens associated with
SCLC and other lung neoplasms to be screened for their
suitability to make ITs with therapeutic potential.
SWA1l-ricin A chain is the most potent IT against human
SCLC yet described and is the first reported IT that recog-
nises a defined SCLC-associated antigen designated the
cluster w4 antigen by the First International Workshop on
SCLC Antigens (Souhami et al., 1988). There is one previous
report of an antibody-toxin conjugate directed against
human SCLC. Weltman et al. (1987) raised hybridoma cell
lines by immtnising animals with the human classic SCLC
cell line NCI-H69, screened supernatants by the indirect
method, and identified a monoclonal antibody that was a
candidate for IT synthesis. An IT constructed from this
antibody and the ribosome-inactivating protein pokeweed
antiviral protein (PAP), was cytotoxic to the NCI-H69 cell
line in tissue culture with an ICso of approximately
2 X IO-9 M. These cytotoxicity experiments were conducted
in the presence of 0.1 M chloroquine, an agent which has
been shown to be capable of enhancing the cytotoxic potency
of ITs containing PAP (Ramakrishnan & Houston, 1984). In
contrast, we have shown that SWA11-ricin A chain was an
effective and selective cytotoxic agent against two human
SCLC cell lines, HC12 and NCI-H69, in the absence of any
potentiating agent. The lower cytotoxic potency of SWA20-
ricin A chain against the HC12 cell line, compared to that of
the SWAl1 IT, may have been a consequence of the lower
level of binding of the SWA20 antibody to the cells com-
pared with the binding of SWAl1. Human SCLC cell lines
expressing higher levels of the cluster 5A antigen could prove
more susceptible to the action of the SWA20 IT.
SWAlI-ricin A chain was about 370- to 1,400-fold less
toxic to the SCLC target cell lines than ricin, indicating that
the entry of the A chain into the cytosol by the antigen-
mediated route was much less efficient than entry via the
route followed by the intact toxin. It is possible that the
potency of the SWA 11 IT could be potentiated by the use of
agents which are capable of altering the intracellular fate of
internalised IT such as the lysosomotropic agents chloro-
quine or ammonium chloride. An alternative approach is
suggested by the studies of Press et al. (1988) who demon-
strated that the potency of ricin A chain ITs directed against
the lymphocyte CD2 antigen depended upon the epitope
recognised by the CD2 monoclonal antibody. Thus, monoc-
lonal antibodies to the cluster w4 antigen that recognise
epitopes different from those recognised by SWAl1 could
form ricin A chain ITs with higher cytotoxic potency against
SCLC cells than the IT made with SWAl1.
Studies with the SWAl1 antibody have previously shown
that it has a high avidity of binding for its target antigen and
that it localises effectively in vivo in a human SCLC tumour
xenograft growing in nude mice (Smith et al., 1989). Further
studies will be directed towards determining the possible
value of ITs made with SWA 11 and with other monoclonal
antibodies recognising the cluster w4 antigen as therapeutic
agents by determining their ability to inhibit the growth of
human SCLC xenografts in experimental animals.
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